New drug targets rare lung cancer gene in phase 2 trial
NCT ID NCT06933329
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 31 times
Summary
This study tests an experimental drug, zelenectide pevedotin, in people with advanced non-small cell lung cancer that has a specific genetic change called NECTIN4 amplification. Participants must have already tried at least one prior cancer treatment. The goal is to see if the drug can shrink tumors and to check its safety. About 73 adults will take part across two groups based on lung cancer subtype.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Complejo Hospitalario Universitario A Coruña
A Coruña, 15006, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Institut Curie
Paris, 75005, France
Conditions
Explore the condition pages connected to this study.